Healthcare Global Enterprises: SEBI Takeover Regulations Disclosure Filing
The disclosure was submitted to NSE on 16 June 2026 under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Regulation 31(4) mandates disclosure when a person acquires or agrees to acquire shares that would give them 25% or more of voting rights. The specific parties, consideration, share count, and acquisition structure are not disclosed in the accessible version of the filing.
Why it mattersRegulation 31(4) disclosure is the mandatory gating item for any open offer or substantial acquisition above 25% threshold; the acquirer's formal disclosure anchors the timeline for public shareholders' protection under Indian takeover law.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026